Maravai LifeSciences Holdings Inc [MRVI] stock is trading at $9.68, up 21.46%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MRVI shares have gain 13.35% over the last week, with a monthly amount glided 7.56%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] stock has seen the most recent analyst activity on August 13, 2024, when Morgan Stanley downgraded its rating to a Equal-Weight and also revised its price target to $10 from $11. Previously, Craig Hallum started tracking the stock with Buy rating on April 10, 2024, and set its price target to $15. On December 12, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $8 on the stock. KeyBanc Capital Markets downgraded its rating to a Sector Weight. Credit Suisse downgraded its rating to a Neutral and reduced its price target to $14 on May 23, 2023. Goldman downgraded its rating to Neutral for this stock on May 09, 2023. In a note dated January 05, 2023, UBS downgraded an Neutral rating on this stock and revised its target price from $20 to $16.
Maravai LifeSciences Holdings Inc [MRVI] stock has fluctuated between $4.52 and $11.56 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] shares were valued at $9.68 at the most recent close of the market. An investor can expect a potential return of 96.28% based on the average MRVI price forecast.
Analyzing the MRVI fundamentals
Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] reported sales of 278.58M for the trailing twelve months, which represents a growth of 6.51%. Gross Profit Margin for this corporation currently stands at 0.42% with Operating Profit Margin at -0.16%, Pretax Profit Margin comes in at 2.14%, and Net Profit Margin reading is -0.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.3 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.39 points at the first support level, and at 7.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.46, and for the 2nd resistance point, it is at 11.24.
Ratios To Look Out For
For context, Maravai LifeSciences Holdings Inc’s Current Ratio is 10.00. Also, the Quick Ratio is 9.28, while the Cash Ratio stands at 8.36. Considering the valuation of this stock, the price to sales ratio is 4.62, the price to book ratio is 3.13.
Transactions by insiders
Recent insider trading involved GTCR INVESTMENT XI LLC, Director, that happened on May 28 ’24 when 9.94 million shares were sold.
